|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q19974623
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010818.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q19974623
|
|
035
|
|
|
‡a
(OCoLC)Q19974623
|
|
043
|
|
|
‡c
NO
|
|
046
|
|
|
‡f
19000526
‡g
19810123
|
|
100
|
0 |
|
‡a
Finn Peter Petersen
‡9
sq
‡9
fr
‡9
en
‡9
de
‡9
da
‡9
ga
‡9
sl
‡9
ca
‡9
es
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
Finn Peter Petersen
‡c
Noors arts (1900-1981)
‡9
nl
|
|
400
|
0 |
|
‡a
Finn Peter Petersen
‡c
médicu noruegu (1900–1981)
‡9
ast
|
|
400
|
0 |
|
‡a
Finn Peter Petersen
‡c
norsk lege og sjakkspiller
‡9
nb
|
|
670
|
|
|
‡a
Author's A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation
|
|
670
|
|
|
‡a
Author's Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma
|
|
670
|
|
|
‡a
Author's Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial
|
|
670
|
|
|
‡a
Author's Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation
|
|
670
|
|
|
‡a
Author's Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies
|
|
670
|
|
|
‡a
Author's Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial
|
|
670
|
|
|
‡a
Author's Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia
|
|
670
|
|
|
‡a
Author's Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders
|
|
670
|
|
|
‡a
Author's Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
|
|
670
|
|
|
‡a
Author's Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
|
|
670
|
|
|
‡a
wikidata site links
‡u
https://no.wikipedia.org/wiki/Finn_Peter_Petersen
|
|
919
|
|
|
‡a
treatmentforacutemyelogenousleukemiabylowdosetotalbodyirradiationbasedconditioningandhematopoieticcelltransplantationfromrelatedandunrelateddonors
‡A
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
‡9
1
|
|
919
|
|
|
‡a
relapseriskinpatientswithmalignantdiseasesgivenallogeneichematopoieticcelltransplantationafternonmyeloablativeconditioning
‡A
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
‡9
1
|
|
919
|
|
|
‡a
reducedintensityconditioningfollowedbyallogeneichematopoieticcelltransplantationforadultpatientswithmyelodysplasticsyndromeandmyeloproliferativedisorders
‡A
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders
‡9
1
|
|
919
|
|
|
‡a
nonmyeloablativeallogeneichematopoieticcelltransplantationinpatientswithacutemyeloidleukemia
‡A
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia
‡9
1
|
|
919
|
|
|
‡a
lowdosetotalbodyirradiationandfludarabineconditioningforhlaclass1mismatcheddonorstemcelltransplantationandimmunologicrecoveryinpatientswithhematologicmalignanciesamulticentertrial
‡A
Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial
‡9
1
|
|
919
|
|
|
‡a
longtermoutcomesamongolderpatientsfollowingnonmyeloablativeconditioningandallogeneichematopoieticcelltransplantationforadvancedhematologicmalignancies
‡A
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies
‡9
1
|
|
919
|
|
|
‡a
graftversushostdiseaseandgraftversustumoreffectsafterallogeneichematopoieticcelltransplantation
‡A
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation
‡9
1
|
|
919
|
|
|
‡a
fludarabineand2gytbiissuperiorto2gytbiasconditioningforhlamatchedrelatedhematopoieticcelltransplantationaphase3randomizedtrial
‡A
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial
‡9
1
|
|
919
|
|
|
‡a
comparisonofoutcomesofhlamatchedrelatedunrelatedorhlahaploidenticalrelatedhematopoieticcelltransplantationfollowingnonmyeloablativeconditioningforrelapsedorrefractoryhodgkinlymphoma
‡A
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma
‡9
1
|
|
919
|
|
|
‡a
randomizedphase2trialoftacrolimusmycophenolatemofetilandsirolimusafternonmyeloablativeunrelateddonortransplantation
‡A
A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
947
|
|
|
‡a
NO
‡9
1
|
|
996
|
|
|
‡2
DBC|87097969899757
|
|
996
|
|
|
‡2
BIBSYS|90849962
|
|
996
|
|
|
‡2
DNB|1055206388
|
|
996
|
|
|
‡2
NTA|220318980
|
|
996
|
|
|
‡2
DBC|87097968818753
|
|
996
|
|
|
‡2
BIBSYS|3063612
|
|
996
|
|
|
‡2
LC|n 88158319
|
|
996
|
|
|
‡2
DBC|87097968172055
|
|
996
|
|
|
‡2
DNB|1157345441
|
|
996
|
|
|
‡2
SELIBR|199884
|
|
996
|
|
|
‡2
RERO|A024526103
|
|
996
|
|
|
‡2
DNB|1351465880
|
|
996
|
|
|
‡2
DBC|87097969041396
|
|
996
|
|
|
‡2
NUKAT|n 2016199244
|
|
996
|
|
|
‡2
LC|n 86830378
|
|
996
|
|
|
‡2
DBC|87097968272378
|
|
996
|
|
|
‡2
ISNI|0000000385023449
|
|
996
|
|
|
‡2
SELIBR|394603
|
|
996
|
|
|
‡2
ISNI|0000000027376711
|
|
996
|
|
|
‡2
BIBSYS|90667229
|
|
996
|
|
|
‡2
BIBSYS|97030808
|
|
996
|
|
|
‡2
SUDOC|249385813
|
|
996
|
|
|
‡2
LC|n 87911665
|
|
996
|
|
|
‡2
BIBSYS|90283404
|
|
996
|
|
|
‡2
DBC|87097968280303
|
|
996
|
|
|
‡2
DBC|87097969052835
|
|
996
|
|
|
‡2
BIBSYS|90790787
|
|
996
|
|
|
‡2
BIBSYS|2132008
|
|
996
|
|
|
‡2
BIBSYS|15011658
|
|
996
|
|
|
‡2
DBC|87097991830345
|
|
997
|
|
|
‡a
1900 1981 lived 0526 0123
‡9
1
|
